Back to the Well: FDA’s Draft Guidance on New Clinical Investigation Exclusivity
- Introduction
FDA recently published a new draft Guidance for Industry titled “New Clinical Investigation Exclusivity (3-Year Exclusivity)...
No More Needles in Haystacks: Congress Requires FDA to Explain Q1/Q2 Sameness
Last week, on February 3, 2026, Congress passed the Consolidated Appropriations Act (“the Act”), providing generic drug manufacturers...
Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed
Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare &...
Entresto Trade Dress Dispute: No Injunctive Relief for Novartis
On July 15, 2025, Judge Evelyn Padin of the District of New Jersey denied Novartis’s motion for preliminary injunction, which would have...
FTC Peeling Back the Layers of the Orange Book
The Federal Trade Commission (FTC) is continuing to pursue pharmaceutical manufacturers for allegedly improperly listing patents in the...
As a free user, you can like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net